Investors who lost money on Beta Bionics, Inc. securities have until November 3, 2026, to ask the court to appoint them lead plaintiff in a securities fraud class action announced by Glancy Prongay Wolke & Rotter LLP. The complaint alleges that, between July 30, 2025, and February 24, 2026, the defendants made materially false or misleading statements and failed to disclose adverse information about the company. The allegations focus on an FDA (U.S. drug regulator) Form 483 and iLet's safety issues, including more than 18,000 complaints and numerous life-threatening hypoglycemic events that Beta Bionics allegedly failed to investigate or report to the FDA without justification. The complaint also challenges statements that remediation efforts were advanced and FDA findings were very benign, as well as the claim that the company could have opened a CAPA (corrective and preventive action process) but did not. No class has been certified, and investors may remain absent class members without taking action.